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Abstract: Since the eradication of smallpox and the subsequent discontinuation of the worldwide
smallpox vaccination program, other Orthopoxviruses beside Variola virus have been increasingly
representing a risk to human health. To investigate the extent of natural contact with Orthopoxviruses
and possible demographic risk factors for such an exposure, we performed a cross-sectional
serosurvey of anti-Orthopoxvirus IgG antibodies in West and Central Africa. To this end, people
living in forest regions in Côte d’Ivoire (CIV, n = 737) and the Democratic Republic of the Congo
(COD, n = 267) were assigned into groups according to their likely smallpox vaccination status.
The overall prevalence of anti-Orthopoxvirus antibodies was 51% in CIV and 60% in COD. High
rates of seropositivity among the vaccinated part of the population (80% in CIV; 96% COD) indicated
a long-lasting post vaccination immune response. In non-vaccinated participants, seroprevalences
of 19% (CIV) and 26% (COD) indicated regular contact with Orthopoxviruses. Multivariate
logistic regression revealed that the antibody level in the vaccinated part of the population
was higher in COD than in CIV, increased with age and was slightly higher in females than
males. In the unvaccinated part of the population none of these factors influenced antibody level
significantly. In conclusion, our results confirm expectedly high anti-Orthopoxvirus seroprevalences
in previously smallpox-vaccinated people living in CIV and the COD but more unexpectedly imply
regular contact with Orthopoxviruses both in Western and Central Africa, even in the absence of
recognized outbreaks.
Keywords: orthopoxvirus; seroprevalence; zoonoses; ELISA (enzyme linked immunosorbent assay)
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1. Introduction
The Orthopoxvirus (OPV) genus comprises several viruses pathogenic to humans, like Cowpox
virus (CPXV), Vaccinia virus (VACV), Monkeypox virus (MPXV), and Variola virus (VARV) [1]. VARV
is the causative agent of smallpox, a devastating infectious disease successfully eradicated about
40 years ago by a world-wide smallpox vaccination campaign [2,3]. Since smallpox vaccination
was also highly protective against other human-pathogenic OPVs, its subsequent cessation has been
increasing the probability of zoonotic OPV infections in humans [4,5]. In Europe, increasing numbers of
documented infections with CPXV are being observed [6,7], while VACV-like viruses cause infections
in South America [8] and MPXV cause infections in Africa [9]. CPXV is transmitted to humans
mainly by direct contact to rodents or cats, and in most cases CPXV causes a self-limiting skin disease.
VACV-like viruses infect dairy workers through direct contact to infected cattle. The infection also
usually results in benign and self-limiting clinical signs, but severe and generalized disease has been
observed in individual cases [10]. Particularly remarkable is the re-occurrence of monkeypox in
forested areas of Western and Central Africa, with frequent reports from the Democratic Republic of
the Congo (COD) [11]. MPXV are causing a disease with clinical signs almost identical to smallpox
(fever, skin pathology), though causing more moderate mortality. For that reason, in the era of
smallpox vaccination, MPXV was not recognized as a discrete entity until the 1970s [12]. Rodents,
such as squirrels of the Funisciurus and Heliociurus genera, are thought to be the reservoir of the
virus and the likely source of human disease [13,14]. Transmission into the human population is
hypothesized to occur through hunting and preparation of food from infected species [15] while
subsequent human-to-human transmission can occur via saliva and respiratory excretions or contact
with lesion exudate and crust material [9,16–18]. The ecological factors that influence host distribution
and viral emergence are not completely understood [11,16].
In contrast to VARV, which could be eradicated by systematic vaccination of those parts of the
human population at risk, the eradication of a zoonotic virus with partially unknown reservoirs
and a broad host-range is all but impossible. The vaccines used previously for the eradication are
efficient but show a poor safety profile, and new vaccines are in the pipeline to be applicable for the
general population, including people with immunological disorders [19]. Antiviral therapeutics are
promising but so far there is no medication licensed to specifically treat poxvirus infections. Even if the
remaining hurdles for compounds like ST-246 [20] and CMX-001 [21] are cleared, the global availability
particularly in developing countries is questionable. Hence it is crucial to monitor human exposure
to MPXV and other OPVs to understand better the ecology of these viruses and their zoonotic hosts
and the dynamics of a possible re-emergence, and perhaps to predict future spill-over events to limit
the number and size of OPV disease outbreaks. The surveillance of human populations that have
substantial contact with rodents and other wildlife through hunting, preparation, and consumption
of bush meat and that engage in agricultural activities in the forest/on the village borders therefore
remains a promising approach for investigating epidemiological patterns of exposure to OPVs in
endemic and non-endemic areas.
We therefore conducted OPV serosurveys in humans living in forest border areas in CIV and the
COD with the intention of investigating possible differences in exposure to OPVs between West and
Central Africa, to identify demographic risk factors for such an exposure and to verify post-vaccination
antibody levels in people that were part of the smallpox eradication program up until 40 years ago.
2. Materials and Methods
2.1. Ethics Statement
All procedures performed in studies involving human participants were in accordance with the
ethical standards of the institutional and/or national research committee and with the 1975 Helsinki
declaration (http://www.wma.net/en/30publications/10policies/b3/) and its later amendments or
comparable ethical standards. Human sampling was approved by the Ivorian ethics commission
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(Comité national d’éthique et de la recherche (CNER), permit number 101 10/MSHP/CNER/P)
and the Congolese ethics commission (Comité d’Éthique, Ministère de l’Enseignement Supérieur et
Universitaire, permit number ESO/CE/018/11, 15 June 2011). Informed consent was obtained from
all participants included in the study. The questionnaire data were treated anonymously.
2.2. Study Populations and Sample Collection
We collected blood samples from participants living in villages bordering tropical rainforests
in CIV and the COD (Figure 1). The study populations are predominantly living on agriculture but
also engage in forest-related activities such as hunting (rodents, primates, and other wild life) and
fishing as well as a range of other village-related occupations. Volunteer participants of all ages were
recruited from 18 villages in CIV (Daobly, Djereoula, Djiboubaye, Gahably, Gouleako, Goulegui Beoue,
Keibly, Pauleoula, Ponan, Portgentil, Sakre, Siobloula, Tai, Tieleoula, Tienkoula, Zagne, Zaipobly,
and Ziriglo) in 2006/2007 and four villages in COD (Bekombo, Ipope, Lompole, and Nganda) in
2011/2012. Three villages in CIV (Gouleako, Ponan, and Tai) were sampled also in 2012. Age and
gender were recorded for each participant. The age value for babies under one year of age was set
to one.
 
Figure 1. Rural sampling locations near Taï National Park, Côte d’Ivoire (left panel) and Salonga National
Park, Democratic Republic of the Congo (right panel). National Parks in dark green. 1, Zagne (Zag).
2, Tienkoula (Tie). 3, Goulegui Beoue (GouB). 4, Djiboubaye (Dji). 5, Keibly (Kei). 6, Zaipobly (Zai).
7, Gahably (Gah). 8, Daobly (Dao). 9, Ponan (Pon). 10, Taï (Tai). 11, Gouleako (Gou). 12, Pauleoula (Pau).
13, Portgentil (Por). 14, Djereoula (Dje). 15, Tienkoula (Tien). 16, Tieleoula (Tiel). 17, Ziriglo (Zir). 18, Sakre
(Sak). 19, Bekombo (Bek). 20, Lompole (Lom). 21, Ipope/Nganda (Ipo/Nga).
Blood was collected by venepuncture into ethylenediaminetetraacetic acid (EDTA) tubes by
medical personnel from the respective countries. After centrifugation, serum was transferred into
cryotubes and stored frozen until laboratory analyses were done at the Robert Koch Institute in
Berlin, Germany.
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All participants of the study were offered a basic clinical examination by a trained medical
professional and, when necessary, free treatment and medical advice were provided. If treatment was
not possible on site, individuals were referred to an appropriate medical facility.
2.3. Definition of the Smallpox Vaccination Status
Participants born up to 1975 (five years before the smallpox eradication declaration in 1980)
were considered vaccinated, participants born between 1975 and 1985 (five years before and after the
declaration of eradication) were considered to have uncertain vaccination status and participants born
after 1985 (five years or more after the declaration of eradication) were considered not vaccinated.
2.4. Enzyme Linked Immunosorbent Assay (ELISA)
Serological tests were done using an in-house enzyme linked immunosorbent assay (ELISA)
which was cross-validated against a neutralization assay and an immunofluorescence assay (IFA).
2.4.1. General Procedure
To establish the in-house ELISA, Hep-2 cells (American Type Culture Collection (ATCC), Manassas,
VA, USA, CCL-23™) or VACV (NYCBOH; ATCC VR-1536™)-infected Hep-2 cells (multiplicity of
infection of 0.2 for 3 to 4 days until all cells detached due to cytopathic effect) were lysed with RIPA
buffer (Thermo Fisher Scientific, Dreieich, Germany; supplemented with HALT™ Protease Inhibitor
Cocktail), and protein content was quantified using a bicinchoninic acid assay (BCA) (Pierce, Dallas,
TX, USA) according to manufacturers’ recommendations. Polysorb™ 96-well microtiter plates (Nunc,
Langenselbold, Germany) were coated with 100 µL of cell lysate (4 µg/mL) in 0.1 M carbonate buffer
(pH 9.6) at 4 ◦C overnight. To account for potential unspecific binding of serum antibodies to cellular
proteins, half of the wells on each plate were coated with lysate of non-infected cells, whereas the
remainder was coated with lysate of VACV-infected cells. The next day, coated plates were washed
four times with 300 µL/well of washing buffer (100 mM Tris, 0.9% NaCl, pH 7.5, 0.05% Tween 20) and
blocked for 1 h at 37 ◦C with 200 µL/well of washing buffer supplemented with 3% bovine serum
albumin (bovine serum albumin) BSA; Carl Roth, Karlsruhe, Germany). Sera were diluted 1:100 in
washing buffer supplemented with 0.25% BSA. After plate washing, 50 µL of diluted sera per well
were incubated on VACV-infected and non-infected cell lysate for 1 h at 37 ◦C. After washing, bound
antibodies were detected with 100 µL/well of 1:5000 diluted HRP-labeled goat anti-human IgG-specific
antibodies (Invitrogen™, Thermo Fisher Scientific). Finally, the enzymatic colorimetric reaction was
performed for 15 min with TMB substrate (Sigma-Aldrich, Taufkirchen, Germany), stopped by adding
1 M sulfuric acid, and analyzed by measuring the optical density at 450 nm with an Infinite200 PRO
microplate reader (Tecan, Maennedorf, Switzerland).
2.4.2. ELISA Data Processing and Normalization
On each ELISA plate a panel of five OPV-negative sera (immunofluorescence assay) IFA titer
< 1:20), two weakly positive sera (IFA titers 1:320) and highly positive (IFA titer 1:10,240) vaccinia
immune globulin (VIG, NR-2632, diluted 1:500; obtained through BEI Resources) was included as an
internal quality control and for data normalization. To this end, first the difference between ELISA
readings of infected and non-infected cell lysate was calculated for each serum. Next, the mean plus
three times the standard deviation of the differences for the five OPV-negative sera was subtracted
from difference values of test sera. Finally, all values were normalized to results obtained for VIG to
minimize plate-to-plate variation (termed antibody level).
2.4.3. Cross Validation by Method Comparison
For cross validation, IFA titers for a panel of 100 sera from German blood donors were determined
as described previously [22]. Additionally, the amount of VACV-neutralizing antibodies was measured
Viruses 2017, 9, 278 5 of 12
for a subpanel of 50 sera by a previously developed neutralization assay [23]. Correlations between
both assays and the ELISA were calculated by either parametric Pearson correlation (between antibody
level and cell index for the neutralization assay) or non-parametric Spearman correlation (between
antibody level and IFA titer for IFA) using Prism 5.04 (GraphPad, La Jolla, CA, USA).
2.4.4. Determination of the Seroprevalence
For prevalence estimations, an antibody level cut-off of 0.05 was used to determine if the sample
was positive or negative. For overall prevalence in the respective countries, all samples irrespective of
vaccination status were included. A 95% confidence interval was calculated for all prevalence estimates.
2.5. Stastistical Analyses
To test whether antibody levels were influenced by age, gender, and/or country, we used a
general linear mixed model [24] into which we simultaneously included these three predictors as fixed
effects. To control for village, this was added as random effect. Data from samples collected in the
main sampling seasons from CIV 2006/2007 and COD 2011/2012 was included, and models were
run separately for the populations defined as unvaccinated and vaccinated, respectively. Participants
with uncertain vaccination status were not included in the statistical models. For the unvaccinated
population, the distribution of antibody levels was positively skewed and transformed through boxcox
transformation (R-package MASS (Modern Applied Statistics with S)) to improve distribution before
entry into the model. For the vaccinated population, age distribution was positively skewed and log
transformed before entry into the model. The models were fitted in R [25] using the function lmer
of the R-package lme4 [26]. We checked for whether the assumptions of normally distributed and
homogenous residuals were fulfilled by visually inspecting a qqplot and the residuals plotted against
fitted values (both indicated no obvious deviation from these assumptions). We checked for model
stability by excluding subjects one at the time from the data which indicated no influential cases to
exist. Variance Inflation Factors [27] were derived using the function vif of the R-package car [28]
applied to a standard linear model excluding the random effects; there was no indication of collinearity
to be an issue. The significance of the full models as compared to the null model (comprising only the
random effect) was established using a likelihood ration test (R function anova with argument test
set to “Chisq”). To achieve more reliable p-values, we fitted the models using Maximum Likelihood
(rather than Restricted Maximum Likelihood) [29]. p-Values for the individual predictors were based
on likelihood ratio tests comparing the full with the respective reduced models (R function drop1) [30].
For comparison of the overall prevalence in the two countries irrespective of vaccination status or
other factors Fischer exact test with the significance level set to 0.5 was used.
2.6. Longitudinal Study of Unvaccinated People in CIV
To test whether antibody levels changed over time, we used samples collected in CIV in
2006/2007 and 2012. We used a general linear mixed model into which we included collection period
(2006/2007 versus 2012) as the fixed effect while controlling for age, gender, and village (random
effect). The distribution of antibody levels was positively skewed and transformed through boxcox
before entry into the models. Fitting the model and checking the assumptions and stability were done
as described above.
3. Results
3.1. Validation of the In-House ELISA
To enable testing of large serum panels for the serological screening, we established an
OPV-specific high-throughput ELISA. To this end, we used whole-cell lysate of VACV-infected cells
to include non-structural or non-surface viral proteins in our antigen mix, as previous studies have
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shown that some of these proteins are highly immunogenic [31,32]. Non-specific antibody binding to
non-viral cellular proteins was addressed by parallel testing of binding to non-infected cell lysate.
For validation, ELISA results were compared to IFA (n = 100) or neutralization test results (n = 50)
(Figure 2). Here, highly significant correlations (p < 0.001) between ELISA and IFA (Spearman r = 0.7984)
as well as ELISA and neutralization assay (Pearson r = 0.6432) indicated a high level of agreement
between the newly established ELISA and the well-established IFA as well as a previously established
neutralization assay. We therefore used our newly established ELISA to detect the seroprevalence
against OPVs.
Figure 2. Comparison of ELISA (enzyme linked immunosorbent assay results) (antibody level) and
IFA (immunofluorescence assay) titer (A) or neutralization assay ((B) XCelligence Cell Index) for a
panel of sera ((A) n = 100; (B) n = 50) collected from German blood donors.
3.2. Serological Screening
The main screening included 737 participants in CIV and 267 participants in COD. In CIV,
379 females and 358 males participated; the median age was 31 years (range 7–95). In COD, 138 females
and 129 males participated; the median age was 30 years (range 1–83). The mean number of samples
collected per village was 45 (range 9 (Bekombo, COD)–103 (Lompole, COD)). Our ELISA revealed
an overall anti-OPV seroprevalence in CIV and COD of 51% (95% CIV 48–55%) and 60% (95% CIV
53–65%), respectively (p = 0.015). (Table 1). The antibody levels with respect to age of the participants
in the respective countries are shown in Figure 3.
Table 1. Anti-OPV seroprevalence in participants living in CIV and COD.
Sample
Côte D’Ivoire Democratic Rep. of the Congo
Prevalence (% (95% CIV)) n Prevalence (% (95% CIV)) n
Overall 51 (48–55) 737 60 (53–65) 267
Vaccinated 80 (75–84) 357 96 (91–99) 112
Females 79 (73–85) 180 98 (90–100) 50
Males 80 (74–85) 177 95 (87–98) 62
Unvaccinated 19 (14–26) 202 26 (18–35) 113
Females 15 (9–23) 101 23 (15–34) 69
Males 24 (17–33) 101 30 (18–44) 44
Resampling unvaccinated 25 (16–37) 75 Not done -
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Figure 3. Antibody levels in human participants in CIV and COD. The red horizontal line indicates
cut-off value for positive samples. The blue vertical line represents time of vaccination cessation;
the green vertical lines indicate the 5-year margins on either side.
3.2.1. Anti-OPV Seroprevalence in Smallpox-Vaccinated Participants
357 and 112 (total 469) participants were assumed to have been vaccinated in CIV and COD,
respectively. Here, the anti-OPV seroprevalence was 80% in CIV (95% confidence interval 75–84%)
and 96% in COD (95% confidence interval 91–99%). The antibody levels ranged from −0.166 to 0.912
(mean 0.317). The regression model itself was highly significant (p < 0.001) and showed that antibody
levels increased with age (p < 0.001, mean increase 0.006 pr. year), and were higher in COD than in
CIV (p < 0.001, mean difference between countries 0.204). There was a small but significant difference
between males and females (mean antibody levels of females were 0.043 higher than those of males,
p = 0.028).
3.2.2. Anti-OPV Seroprevalence in Smallpox Non-Vaccinated Participants
202 and 113 participants were assumed not to have been vaccinated in CIV and COD, respectively.
The OPV seroprevalence was 19% in CIV (95% confidence interval 14–26%) and 26% in COD (95%
confidence interval 18–35%). The antibody levels ranged from −0.202 to 0.797 (mean 0.023). Country,
gender, and age had no significant effect on antibody levels (p = 0.233 for overall model). The median
antibody level per village for the unvaccinated population is shown in Figure 4.
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Figure 4. Mean antibody levels in the villages where specimens were taken. The names of the villages
are abbreviated to the first three or four letters of the name. The first 18 villages on the left are in CIV,
the 4 on the right hand side represents villages in COD.
Here, no statistical significant differences between the different villages samples were detected
regarding antibody level.
3.2.3. Anti-OPV Seroprevalence in Participants with Unclear Smallpox Vaccination Status
178 people in CIV and 42 people in COD had an unclear vaccination status and were excluded
from further statistical analyses. The seroprevalence for these participants was 29% (95% confidence
interval 23–37) in CIV and 55% (95% confidence interval 39–70) in COD.
3.2.4. Longitudinal Study of Unvaccinated Participants in CIV
In a resampling in 2012, five years after the original sampling in 2006/2007, 75 new specimens
from unvaccinated participants were collected in CIV. The OPV seroprevalence in these specimens was
25% (95% confidence interval 16–37%) compared to 19% (95% confidence interval 14–26%) in 2006/2007.
However, this increase in anti-OPV-specific antibody levels between the specimens collected from
unvaccinated participants in the two sampling periods was not statistically significant controlling for
age and gender (mean antibody level 0.055 higher in resampling, p = 0.082).
4. Discussion
In our study, we assessed the anti-OPV seroprevalence in CIV and COD. The overall anti-OPV
seroprevalence was 51% (95% confidence interval 48–55) in CIV and 60% (95% confidence interval
53–65) in COD. As with many comparable studies, our “country level” is based on sampling from
selected villages in particular areas and might not be representative of the two countries as a whole,
considering that the populations of CIV and COD are approximately 26 and 75 million people,
respectively. Moreover, the antibody prevalence might vary even between relatively close geographical
areas [33]. Some studies in Ghana and the Republic of Congo report overall anti-OPV seroprevalences
of 53% [33] and 57% [34] based on ELISAs, respectively, which is similar to our results. However,
other studies employing haemagglutination-inhibition tests describe lower overall seroprevalences in
COD (19%, [35]) and Republic of Congo (16%, [36]).
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We found that the anti-OPV seroprevalence in smallpox-vaccinated participants in both countries
was indeed high with 80% and 96% in CIV and COD, respectively. These results indicate first of
all a long-lived immune response after smallpox vaccination and confirm the findings of previous
studies [37–39]. Both a higher rate of initial vaccination in the COD population as well as repeated
contact to circulating OPV might explain the slightly higher overall seroprevalence observed in this
population. However, as our presumable vaccination status was based solely on age and we do not
have more data on possible OPV exposure we cannot fully explain this observed difference. Our model
showed that the antibody levels of vaccinated participants were influenced by country, age, and gender:
the level was significantly higher in COD than in CIV, increased with age, and was a slightly higher
in women than men. The OPV seroprevalence in smallpox-unvaccinated participants was 19% and
26% in CIV and COD, respectively, and, although we did observe a slight increase, it did not change
significantly over time in CIV. These sero-positive, previously unvaccinated people are most likely
representative for natural contacts to OPVs. The OPV most prominent in Africa, after the smallpox
eradication, is MPXV. According to the literature, there are increasing numbers of MPXV infections
in Central Africa, with the COD being a hotspot [4]. Interestingly, we observed no difference in
prevalence and antibody level between the CIV and the COD, indicating that the overall exposure to
OPVs is the same, and that the relatively higher number of MPXV cases in COD does not make up for
a large part of the overall OPV exposure.
While the higher virulence of the Congo clade of MPXV partly explains the larger case numbers
observed in COD, a possible explanation for the overall similar seroprevalence of anti-OPV antibodies
is that OPVs other than MPXV may be circulating in African countries [40]. Furthermore, the host-range
of some OPV is broad and the variety of potential animal reservoirs is extremely high, with many
species (such as rodents) living in close contact with humans. Due to the conserved antigenic epitopes
among the OPVs, it is not possible to accurately differentiate the immune response to different OPVs
with serological techniques [31,41]. Although it seems likely that MPXV contributes to the anti-OPV
seroprevalence, at least in endemic regions like the COD, other OPVs should also be considered [33].
Unfortunately, we have no information on suspected skin aberrations of these study participants
that could support the seroprevalence data. However, MPXV may also cause subclinical infections
which might account for seroconversion in some people [42]. Promising MPXV-specific peptide-based
ELISAs might be useful in differentiating between MPXV-specific antibodies and anti-OPV antibodies
in the future [43].
As 19% and 26% of unvaccinated participants in CIV and COD are seropositive for OPV, these data
indicate at the same time that 81% and 74% of the people who are born after the smallpox vaccination
campaign are seronegative for OPV and hence would be sensitive to OPV infections like MPXV.
Although the degree of protection afforded by IgG antibodies cannot be determined accurately,
the presence of anti-OPV antibodies likely provides some level of protection. It is important to
further investigate the long-term dynamics of anti-OPV antibodies and pox disease occurrence, as the
population structure will change and the proportion of unvaccinated people will increase. In addition,
the age of unvaccinated people will increase and risk factors might become more evident. This effect
has already been shown by comparing the age of monkeypox patients in different studies; during
surveys in the 1970s and 80s, the majority of the cases were children and the mean age was about
4.5 years. In the surveys performed two decades later, the majority of the patients were older than
25 years and the mean age was approximately fifteen years old [42].
It is not clear why monkeypox occurs more frequently in the Congo Basin than in other African
regions. This can only partly be explained by the fact that the Central African strains are more virulent
and able to cause human-to-human transmission more efficiently than the West African strains [44–46].
Human cases of monkeypox have not been reported in West Africa for decades, although ecological
niche models predict areas of suitable ecology in this part of Africa and wildlife studies show that
MPXV is indeed present [11,13,16,47].
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5. Conclusions
Our data show that, even after the eradication of Variola virus, infections with OPVs occur in
Africa. These results highlight the need for future monitoring of OPVs in human populations in
tropical Africa. Further studies should ideally be multidisciplinary, combining serological monitoring,
clinical epidemiology, and human anthropology to complement reservoir, ecology, and climate studies.
This way, the disciplines can be synergized to increase our understanding of, and possibly even predict
and prevent, spill-over events [16–18].
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